Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: Pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae

International Journal of Antimicrobial Agents

Volumn 26, Issue 2, 2005, Pages 120-125

  Noreddin, Ayman M ^a,b   Hoban, Daryl J ^b,c   Zhanel, George G ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Community acquired pneumonia; Gatifloxacin; Levofloxacin; Monte Carlo analysis; Target attainment

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG HALF LIFE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; MIDDLE AGED; MONTE CARLO METHOD; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; PREDICTIVE VALUE OF TESTS; STREPTOCOCCUS PNEUMONIAE;

EID: 22544460247     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.04.012     Document Type: Article

References (34)

1. J.P. Lynch, and F.J. Martinez Community-acquired pneumonia Curr Opin Pulm Med 4 1988 162 172
2. M.J. Fine, M.A. Smith, and C.A. Carson Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis J Am Med Assoc 275 1996 134 141
3. J.G. Bartlett, R.F. Breiman, L.A. Mandell, and T.M. File Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America Clin Infect Dis 26 1988 811 838
4. H. Mikamo, K. Kawazoe, Y. Sato, K. Izumi, and T. Tamaya Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis J Antimicrob Chemother 41 1988 131 133
5. M.P. Montanari, M. Mingoia, F. Marchetti, and P.E. Varaldo In vitro activity of levofloxacin against gram-positive bacteria Chemotherapy 45 1999 411 417
6. G.G. Zhanel, and A.M. Noreddin Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections Curr Opin Pharmacol 1 2001 459 463
7. J.C. Fung-Tomc, B. Minassian, and B. Kolek Antibacterial spectrum of a novel des-fluoro(6) quinolone BMS-284756 Antimicrob Agents Chemother 44 2000 3351 3356
8. J.A. Hoogkamp-Korstanje In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections J Antimicrob Chemother 40 1997 427 431
9. D.E. King, R. Malone, and S.H. Lilley New classification and update on the quinolone antibiotics Am Fam Physician 61 2000 2741 2748
10. M.K. Lacy, W. Lu, and X. Xu Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection Antimicrob Agents Chemother 43 1999 672 677
11. P.D. Lister, and C.C. Sanders Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae J Antimicrob Chemother 43 1999 79 86
12. G.G. Zhanel, K. Ennis, and L. Vercaigne A critical review of the fluoroquinolones: focus on respiratory infections Drugs 62 2002 13 59
13. J.K. Thomas, A. Forrest, and S.M. Bhavnani Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy Antimicrob Agents Chemother 42 1998 521 527
14. P.G. Ambrose, and D.M. Gradela The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae Diagn Microbiol Infect Dis 28 2000 151 157
15. M. Hurst, H.M. Lamb, L.J. Scott, and D.P. Figgitt Levofloxacin: an updated review of its use in the treatment of bacterial infections Drugs 62 2002 2127 2167
16. Bellyou T, Palatnick L, Rimmer E, Nichol K, Zhanel GG, Hoban DJ. Incidence of penicillin, doxycycline, macrolide and fluoroquinolone resistant Streptococcus pneumoniae (SPN) in Canada: results of the Canadian Respiratory Organism Susceptibility Study (CROSS), 1997-2002. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; 27-30 September 2002. Washington, DC: American Society for Microbiology; 2002. Abstract C2-1633, p. 110.
17. P.G. Ambrose, D.M. Grasela, T.H. Grasela, J. Passarell, H.B. Mayer, and P.F. Pierce Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections Antimicrob Agents Chemother 45 2001 2793 2797
18. S.L. Preston, G.L. Drusano, and A.L. Berman Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection Antimicrob Agents Chemother 42 1998 1098 1104
19. G.G. Zhanel, J.A. Karlowsky, L. Palatnick, L. Vercaigne, D.E. Low, and D.J. Hoban Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian National Surveillance Study. The Canadian Respiratory Infection Study Group Antimicrob Agents Chemother 43 1999 2504 2509
20. D.E. Burmaster, and P.D. Anderson Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments Risk Anal 14 1994 477 481
21. J.M. Hammersley, and D.C. Handscomb Monte Carlo simulation Monte Carlo methods 1964 Methuen & Co. Ltd. London, UK
22. K.M. Thompson, D.E. Burmaster, and E.A.C. Crouch Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments Risk Anal 12 1992 53 63
23. M.J. Fine, T.E. Auble, and D.M. Yealy A prediction rule to identify low-risk patients with community-acquired pneumonia N Engl J Med 336 1997 243 250
24. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10 [Quiz 11-2]
25. A. Forrest, S. Chodosh, M.A. Amantea, D.A. Collins, and J.J. Schentag Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis J Antimicrob Chemother 40 Suppl. a 1997 45 57
26. A. Forrest, D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 37 1993 1073 1081
27. M.K. Lacy, W. Lu, and X. Xu Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection Antimicrob Agents Chemother 43 1999 672 677
28. P.G. Ambrose, D.M. Grasela, T.H. Grasela, J. Passarell, H.B. Mayer, and P.F. Pierce Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections Antimicrob Agents Chemother 45 2001 2793 2797
29. P.G. Ambrose Jr., R.C. Owens, and D. Grasela Antimicrobial pharmacodynamics Med Clin North Am 84 2000 1431 1446
30. E. Hershberger, and M.J. Rybak Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model Antimicrob Agents Chemother 44 2000 598 601
31. P.D. Lister Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication Antimicrob Agents Chemother 46 2002 69 74
32. T.M. File Jr., J. Segreti, and L. Dunbar A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia Antimicrob Agents Chemother 41 1997 1965 1972
33. L.M. Dunbar, R.G. Wunderink, and M.P. Habib High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm Clin Infect Dis 37 2003 752 760
34. C.H. Nightingale, E.M. Grant, and R.X. Quintiliani Pharmacodynamics and pharmacokinetics of levofloxacin Chemotherapy 46 2002 6 14